{
    "clinical_study": {
        "@rank": "117857", 
        "arm_group": [
            {
                "arm_group_label": "Part B", 
                "arm_group_type": "Other", 
                "description": "Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan."
            }, 
            {
                "arm_group_label": "Part A", 
                "arm_group_type": "Other", 
                "description": "Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the Drug-Drug(telmisartan, amlodipine and/ or\n      chlorthalidone) interaction and safety in healthy adult volunteers."
        }, 
        "brief_title": "Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Participant who has a body weight that is \u226555kg(male) or \u226550kg(female) with ideal\n             body weight of 80-120% (ideal body weight)\n\n          2. Who has not suffered from clinically significant disease\n\n          3. Provision of signed written informed consent\n\n        Exclusion Criteria:\n\n          1. History of and clinically significant disease psychiatric, or malignancy.\n\n          2. A history of drug abuse or the presence of positive reactions to drugs that have\n             abuse potential in urine screenings for drugs.\n\n          3. Administration of other investigational products within 3 months prior to the first\n             dosing.\n\n          4. Administration of herbal medicine within 2 weeks or administration of ethical drugs\n             within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior\n             to the first dosing of the investigational product (if the investigator (study\n             doctor) determines that the person meets other criteria appropriately, the relevant\n             person may participate in the study).\n\n          5. Volunteers considered not eligible for the clinical trial by the investigator (study\n             doctor) due to reasons including laboratory test results, ECGs, or vital signs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152969", 
            "org_study_id": "YH22162-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part B", 
                    "Part A"
                ], 
                "intervention_name": "Telmisartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part B", 
                    "Part A"
                ], 
                "intervention_name": "Amlodipine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part B", 
                    "Part A"
                ], 
                "intervention_name": "Chlorthalidone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chlorthalidone", 
                "Amlodipine", 
                "Telmisartan", 
                "Benzoates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 1, 2014", 
        "location": {
            "contact": {
                "email": "calm100@catholic.ac.kr", 
                "last_name": "Seunghoon Han", 
                "phone": "82-2-2258-7888"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "The Catholic University of Korea Seoul St.Mary's Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers", 
        "overall_contact": {
            "email": "calm100@catholic.ac.kr", 
            "last_name": "Seung Hoon Han", 
            "phone": "82-2-2258-7888"
        }, 
        "overall_official": {
            "affiliation": "The Catholic University of Korea", 
            "last_name": "Dong Seok Yim", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "AUCt ss, Cmax ss of telmisartan/amlodipine/chlorthalidone", 
            "safety_issue": "No", 
            "time_frame": "Totally 28points for 24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152969"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Cmin ss, tmax ss, t1/2 of telmisartan/amlodipine/chlorthalidone", 
            "safety_issue": "No", 
            "time_frame": "Totally 28points for 24 hours"
        }, 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}